COURTNEY MYERS: Open Payments
NPI 1023774353 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,913 in 104 payments from 14 companies in 2025. Trend: 2023 $1,330 · 2024 $2,039 · 2025 $1,913
Food & beverage: $1,913
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $565 |
| Janssen Biotech, Inc. | 13 | $255 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $237 |
| Regeneron Healthcare Solutions, Inc. | 4 | $102 |
| Gilead Sciences, Inc. | 5 | $95 |
| Lilly USA, LLC | 4 | $94 |
| Ipsen Biopharmaceuticals, Inc | 5 | $82 |
| GENZYME CORPORATION | 4 | $81 |
| Biocon Biologics Inc | 3 | $61 |
Products named: RINVOQ, TREMFYA, ENTYVIO, XIFAXAN, DUPIXENT, SKYRIZI, OMVOH, IQIRVO.
Industry payments across OK — which companies pay providers there.
